Monitoring soluble cMET and ctDNA in metastatic uveal melanoma patients to track early disease progression on immunotherapies
Soluble cMET might serve as a tumor-specific biomarker to predict clinical outcomes in mUM patients. A combinational assessment of scMET and ctDNA in mUM patients' blood offers a highly sensitive potential approach to monitor early disease progression under immunotherapies with ICI or tebentafusp.
Authors
- Daniel Hübschmann (ORCID: https://orcid.org/0000-0002-6041-7049)
- Francisco García-Asencio (ORCID: https://orcid.org/0000-0002-8641-3839)
- Bénédicte Lenoir (ORCID: https://orcid.org/0000-0002-3540-9688)
- Jörg Richter (ORCID: https://orcid.org/0000-0002-5823-9618)
- Melanie Wiecken
- Christian H. Ziener (ORCID: https://orcid.org/0000-0001-8854-7358)
- Elena Clementi
- Devayani Machiraju (ORCID: https://orcid.org/0009-0008-7421-7356)
- Jessica Cecile Hassel (ORCID: https://orcid.org/0000-0001-7575-6230)
- Jennifer Hüllein
- Dirk Jäger
Institutions
- German Cancer Research Center (DE)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- Molecular Partners (Switzerland) (CH)
- National Center for Tumor Diseases (DE)
- Heidelberg Institute for Stem Cell Technology and Experimental Medicine (DE)
- University Medical Centre Mannheim (DE)
- Deutsches Konsortium für Translationale Krebsforschung (DE)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-07-19
- DOI
- https://doi.org/10.1186/s13046-025-03451-2
- Citations
- 2
- Primary Topic
- Ocular Oncology and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.41
Funders
- Deutsche Forschungsgemeinschaft
- Universitätsklinikum Heidelberg